Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Recommendation of “Hold” by Brokerages

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has been given a consensus rating of “Hold” by the five analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $38.6667.

A number of equities research analysts have commented on PHAR shares. Canaccord Genuity Group increased their price target on Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Wall Street Zen lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Finally, Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st.

Pharming Group Stock Performance

Shares of PHAR stock opened at $11.85 on Thursday. The business’s fifty day simple moving average is $12.63 and its 200-day simple moving average is $14.44. The company has a market cap of $838.74 million, a PE ratio of 98.75 and a beta of -0.01. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. Pharming Group has a 12-month low of $9.62 and a 12-month high of $21.34.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. Analysts expect that Pharming Group will post 0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group in the 4th quarter valued at $224,000. NewEdge Advisors LLC raised its stake in Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares during the last quarter. Millennium Management LLC acquired a new stake in Pharming Group during the 4th quarter worth about $360,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in Pharming Group during the 2nd quarter worth about $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.